Tissue Factor in Cervical Cancer and Immunotherapy with hI-con1
Author Information
Author(s): Cocco Emiliano, Varughese Joyce, Buza Natalia, Bellone Stefania, Glasgow Michelle, Bellone Marta, Todeschini Paola, Carrara Luisa, Silasi Dan-Arin, Azodi Masoud, Schwartz Peter E, Rutherford Thomas J, Pecorelli Sergio, Lockwood Charles J, Santin Alessandro D
Primary Institution: Yale University School of Medicine
Hypothesis
The study evaluates the expression of Tissue Factor (TF) in cervical cancer and the potential of hI-con1 as a novel immunotherapy.
Conclusion
hI-con1 induces strong cytotoxicity against cervical cancer cell lines that overexpress TF, suggesting it may be a new treatment for cervical cancer.
Supporting Evidence
- 100% of cervical cancer cell lines tested expressed high levels of Tissue Factor.
- All primary cervical cancer cell lines overexpressing TF were highly sensitive to hI-con1-induced cytotoxicity.
- Low doses of interleukin-2 increased the cytotoxic effect of hI-con1.
Takeaway
Cervical cancer cells have a lot of a protein called Tissue Factor, and a new treatment called hI-con1 can help kill these cancer cells.
Methodology
The study used immunohistochemistry, real-time PCR, and flow cytometry to evaluate TF expression and assessed cytotoxicity using chromium-release assays.
Limitations
The study is limited to in vitro experiments and may not fully represent in vivo responses.
Participant Demographics
The study included 11 patients with cervical cancer, with a mix of squamous and adenocarcinoma histology.
Statistical Information
P-Value
p = 0.0023 (qRT-PCR); p = 0.0042 (flow cytometry); p = 0.025 (IL-2 enhancement)
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website